Skip to main content
Erschienen in: Cancer and Metastasis Reviews 1/2020

24.02.2020

Pediatric medulloblastoma in the molecular era: what are the surgical implications?

verfasst von: Michelle M. Kameda-Smith

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Pediatric brain tumors are the leading cause of childhood cancer mortality with medulloblastoma (MB) representing the most frequent malignant tumor. Although standardization of therapy resulted in a 2-fold reduction in mortality in patients with MB by 2002, it became clear that further improvements in clinical outcome would require a deeper understanding of the biology of MB. Employing the four main molecular MB subgroups (Wnt, Shh, Group 3 and Group 4), a restratification into clinicogenomic risk categories quantified an unacceptable survival for the high-risk group, urging researchers to focus their efforts towards acquiring a greater biological understanding of these children. Advancing in parallel with the molecular characterization and understanding of pediatric MB is the clinicogenomic correlations giving rise to recommendations for neurosurgical care. While unique observations that distinct radiological patterns can be identified to inform the MB molecular subgroup preoperatively, current neurosurgical practice remains maximal safe surgical resection followed by risk-adapted provision of adjuvant therapy in the context of a clinical trial.
Literatur
1.
Zurück zum Zitat Ellison, D. W., et al. (2011). Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica, 121(3), 381–396.CrossRefPubMedPubMedCentral Ellison, D. W., et al. (2011). Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica, 121(3), 381–396.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Bailey, P., Cushings H. (1925). Medulloblastoma cerebelli:a common type of midcerebellar glioma of childhood. Archives of Neurology and Psychiatry, 14, 192–224.CrossRef Bailey, P., Cushings H. (1925). Medulloblastoma cerebelli:a common type of midcerebellar glioma of childhood. Archives of Neurology and Psychiatry, 14, 192–224.CrossRef
3.
Zurück zum Zitat Polkinghorn, W. R., & Tarbell, N. J. (2007). Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nature Clinical Practice. Oncology, 4(5), 295–304.CrossRefPubMed Polkinghorn, W. R., & Tarbell, N. J. (2007). Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nature Clinical Practice. Oncology, 4(5), 295–304.CrossRefPubMed
4.
Zurück zum Zitat Ellison, D. (2002). Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathology and Applied Neurobiology, 28(4), 257–282.CrossRefPubMed Ellison, D. (2002). Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathology and Applied Neurobiology, 28(4), 257–282.CrossRefPubMed
5.
Zurück zum Zitat Packer, R. J. (2007). Craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. Current Neurology and Neuroscience Reports, 7(2), 130–132. Packer, R. J. (2007). Craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. Current Neurology and Neuroscience Reports, 7(2), 130–132.
6.
Zurück zum Zitat Packer, R. J., Sutton, L. N., Atkins, T. E., Radcliffe, J., Bunin, G. R., D’Angio, G., Siegel, K. R., & Schut, L. (1989). A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. Journal of Neurosurgery, 70(5), 707–713.CrossRefPubMed Packer, R. J., Sutton, L. N., Atkins, T. E., Radcliffe, J., Bunin, G. R., D’Angio, G., Siegel, K. R., & Schut, L. (1989). A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. Journal of Neurosurgery, 70(5), 707–713.CrossRefPubMed
7.
Zurück zum Zitat Bull, K. S., et al. (2014). Child-related characteristics predicting subsequent health-related quality of life in 8- to 14-year-old children with and without cerebellar tumors: a prospective longitudinal study. Neurooncol Pract, 1(3), 114–122.PubMedPubMedCentral Bull, K. S., et al. (2014). Child-related characteristics predicting subsequent health-related quality of life in 8- to 14-year-old children with and without cerebellar tumors: a prospective longitudinal study. Neurooncol Pract, 1(3), 114–122.PubMedPubMedCentral
8.
Zurück zum Zitat Ellison, D. W. (2010). Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathologica, 120(3), 305–316.CrossRefPubMed Ellison, D. W. (2010). Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathologica, 120(3), 305–316.CrossRefPubMed
9.
Zurück zum Zitat Ris, M. D., Packer, R., Goldwein, J., Jones-Wallace, D., & Boyett, J. M. (2001). Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. Journal of Clinical Oncology, 19(15), 3470–3476.CrossRefPubMed Ris, M. D., Packer, R., Goldwein, J., Jones-Wallace, D., & Boyett, J. M. (2001). Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. Journal of Clinical Oncology, 19(15), 3470–3476.CrossRefPubMed
10.
Zurück zum Zitat Palmer, S. L., et al. (2003). Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology, 17(4), 548–555.CrossRefPubMed Palmer, S. L., et al. (2003). Predicting intellectual outcome among children treated with 35-40 Gy craniospinal irradiation for medulloblastoma. Neuropsychology, 17(4), 548–555.CrossRefPubMed
11.
Zurück zum Zitat Palmer, S. L., et al. (2001). Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. Journal of Clinical Oncology, 19(8), 2302–2308. Palmer, S. L., et al. (2001). Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. Journal of Clinical Oncology, 19(8), 2302–2308.
12.
Zurück zum Zitat Mulhern, R. K., Merchant, T. E., Gajjar, A., Reddick, W. E., & Kun, L. E. (2004). Late neurocognitive sequelae in survivors of brain tumours in childhood. The Lancet Oncology, 5(7), 399–408.CrossRefPubMed Mulhern, R. K., Merchant, T. E., Gajjar, A., Reddick, W. E., & Kun, L. E. (2004). Late neurocognitive sequelae in survivors of brain tumours in childhood. The Lancet Oncology, 5(7), 399–408.CrossRefPubMed
13.
Zurück zum Zitat Yoo, H. J., Kim, H., Park, H. J., Kim, D. S., Ra, Y. S., & Shin, H. Y. (2016). Neurocognitive function and health-related quality of life in pediatric Korean survivors of medulloblastoma. Journal of Korean Medical Science, 31(11), 1726–1734.CrossRefPubMedPubMedCentral Yoo, H. J., Kim, H., Park, H. J., Kim, D. S., Ra, Y. S., & Shin, H. Y. (2016). Neurocognitive function and health-related quality of life in pediatric Korean survivors of medulloblastoma. Journal of Korean Medical Science, 31(11), 1726–1734.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Golub, T. R., et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286(5439), 531–537.CrossRefPubMed Golub, T. R., et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286(5439), 531–537.CrossRefPubMed
15.
Zurück zum Zitat Pomeroy, S. L., et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415(6870), 436–442.CrossRefPubMed Pomeroy, S. L., et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415(6870), 436–442.CrossRefPubMed
16.
Zurück zum Zitat Thompson, M. C., Fuller, C., Hogg, T. L., Dalton, J., Finkelstein, D., Lau, C. C., Chintagumpala, M., Adesina, A., Ashley, D. M., Kellie, S. J., Taylor, M. D., Curran, T., Gajjar, A., & Gilbertson, R. J. (2006). Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. Journal of Clinical Oncology, 24(12), 1924–1931.CrossRefPubMed Thompson, M. C., Fuller, C., Hogg, T. L., Dalton, J., Finkelstein, D., Lau, C. C., Chintagumpala, M., Adesina, A., Ashley, D. M., Kellie, S. J., Taylor, M. D., Curran, T., Gajjar, A., & Gilbertson, R. J. (2006). Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. Journal of Clinical Oncology, 24(12), 1924–1931.CrossRefPubMed
17.
Zurück zum Zitat Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N. S., Caron, H. N., Cloos, J., Mrsić, A., Ylstra, B., Grajkowska, W., Hartmann, W., Pietsch, T., Ellison, D., Clifford, S. C., & Versteeg, R. (2008). Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One, 3(8), e3088.CrossRefPubMedPubMedCentral Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N. S., Caron, H. N., Cloos, J., Mrsić, A., Ylstra, B., Grajkowska, W., Hartmann, W., Pietsch, T., Ellison, D., Clifford, S. C., & Versteeg, R. (2008). Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One, 3(8), e3088.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., Rutka, J. T., Pfister, S., & Taylor, M. D. (2011). Medulloblastoma comprises four distinct molecular variants. Journal of Clinical Oncology, 29(11), 1408–1414.CrossRefPubMed Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., Rutka, J. T., Pfister, S., & Taylor, M. D. (2011). Medulloblastoma comprises four distinct molecular variants. Journal of Clinical Oncology, 29(11), 1408–1414.CrossRefPubMed
19.
Zurück zum Zitat Cho, Y. J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C. G., Lau, C. C., Olson, J. M., Gilbertson, R. J., Gajjar, A., Delattre, O., Kool, M., Ligon, K., Meyerson, M., Mesirov, J. P., & Pomeroy, S. L. (2011). Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of Clinical Oncology, 29(11), 1424–1430.CrossRefPubMed Cho, Y. J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C. G., Lau, C. C., Olson, J. M., Gilbertson, R. J., Gajjar, A., Delattre, O., Kool, M., Ligon, K., Meyerson, M., Mesirov, J. P., & Pomeroy, S. L. (2011). Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. Journal of Clinical Oncology, 29(11), 1424–1430.CrossRefPubMed
20.
Zurück zum Zitat Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., Ellison, D. W., Lichter, P., Gilbertson, R. J., Pomeroy, S. L., Kool, M., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 123(4), 465–472.CrossRefPubMed Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., Ellison, D. W., Lichter, P., Gilbertson, R. J., Pomeroy, S. L., Kool, M., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 123(4), 465–472.CrossRefPubMed
21.
Zurück zum Zitat Kool, M., Korshunov, A., Remke, M., Jones, D. T., Schlanstein, M., Northcott, P. A., Cho, Y. J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., Clifford, S. C., Pietsch, T., von Bueren, A., Rutkowski, S., McCabe, M., Collins, V. P., Bäcklund, M. L., Haberler, C., Bourdeaut, F., Delattre, O., Doz, F., Ellison, D. W., Gilbertson, R. J., Pomeroy, S. L., Taylor, M. D., Lichter, P., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathologica, 123(4), 473–484.CrossRefPubMedPubMedCentral Kool, M., Korshunov, A., Remke, M., Jones, D. T., Schlanstein, M., Northcott, P. A., Cho, Y. J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., Clifford, S. C., Pietsch, T., von Bueren, A., Rutkowski, S., McCabe, M., Collins, V. P., Bäcklund, M. L., Haberler, C., Bourdeaut, F., Delattre, O., Doz, F., Ellison, D. W., Gilbertson, R. J., Pomeroy, S. L., Taylor, M. D., Lichter, P., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathologica, 123(4), 473–484.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Clifford, S. C., Lusher, M. E., Lindsey, J. C., Langdon, J. A., Gilbertson, R. J., Straughton, D., & Ellison, D. W. (2006). Wnt/wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle, 5(22), 2666–2670.CrossRefPubMed Clifford, S. C., Lusher, M. E., Lindsey, J. C., Langdon, J. A., Gilbertson, R. J., Straughton, D., & Ellison, D. W. (2006). Wnt/wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle, 5(22), 2666–2670.CrossRefPubMed
23.
Zurück zum Zitat Ellison, D. W., et al. (2005). Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology, 23(31), 7951–7957.CrossRefPubMed Ellison, D. W., et al. (2005). Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology, 23(31), 7951–7957.CrossRefPubMed
24.
Zurück zum Zitat Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica, 131(6), 803–820.CrossRefPubMed Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica, 131(6), 803–820.CrossRefPubMed
25.
Zurück zum Zitat Ramaswamy, V., Remke M, Bouffet E., Bailey S., Clifford SC., et al. (2016). Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 131(6), 821–31. Ramaswamy, V., Remke M, Bouffet E., Bailey S., Clifford SC., et al. (2016). Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 131(6), 821–31.
26.
Zurück zum Zitat Johnston, D. L., et al. (2018). Survival following tumor recurrence in children with medulloblastoma. Journal of Pediatric Hematology/Oncology. Johnston, D. L., et al. (2018). Survival following tumor recurrence in children with medulloblastoma. Journal of Pediatric Hematology/Oncology.
27.
Zurück zum Zitat Johnston, D. L., Keene, D., Kostova, M., Lafay-Cousin, L., Fryer, C., Scheinemann, K., Carret, A. S., Fleming, A., Percy, V., Afzal, S., Wilson, B., Bowes, L., Zelcer, S., Mpofu, C., Silva, M., Larouche, V., Brossard, J., Strother, D., & Bouffet, E. (2015). Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive. Journal of Neuro-Oncology, 124(2), 247–253.CrossRefPubMed Johnston, D. L., Keene, D., Kostova, M., Lafay-Cousin, L., Fryer, C., Scheinemann, K., Carret, A. S., Fleming, A., Percy, V., Afzal, S., Wilson, B., Bowes, L., Zelcer, S., Mpofu, C., Silva, M., Larouche, V., Brossard, J., Strother, D., & Bouffet, E. (2015). Survival of children with medulloblastoma in Canada diagnosed between 1990 and 2009 inclusive. Journal of Neuro-Oncology, 124(2), 247–253.CrossRefPubMed
28.
Zurück zum Zitat Koschmann, C., et al. (2016). Survival after relapse of medulloblastoma. Journal of Pediatric Hematology/Oncology, 38(4), 269–273.CrossRefPubMed Koschmann, C., et al. (2016). Survival after relapse of medulloblastoma. Journal of Pediatric Hematology/Oncology, 38(4), 269–273.CrossRefPubMed
29.
Zurück zum Zitat Sabel, M., Fleischhack, G., Tippelt, S., Gustafsson, G., Doz, F., Kortmann, R., Massimino, M., Navajas, A., von Hoff, K., Rutkowski, S., Warmuth-Metz, M., Clifford, S. C., Pietsch, T., Pizer, B., Lannering, B., & SIOP-E Brain Tumour Group. (2016). Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. Journal of Neuro-Oncology, 129(3), 515–524.CrossRefPubMedPubMedCentral Sabel, M., Fleischhack, G., Tippelt, S., Gustafsson, G., Doz, F., Kortmann, R., Massimino, M., Navajas, A., von Hoff, K., Rutkowski, S., Warmuth-Metz, M., Clifford, S. C., Pietsch, T., Pizer, B., Lannering, B., & SIOP-E Brain Tumour Group. (2016). Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. Journal of Neuro-Oncology, 129(3), 515–524.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Bowers, D. C., Gargan, L., Weprin, B. E., Mulne, A. F., Elterman, R. D., Munoz, L., Giller, C. A., & Winick, N. J. (2007). Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma. Journal of Neurosurgery, 107(1 Suppl), 5–10.PubMed Bowers, D. C., Gargan, L., Weprin, B. E., Mulne, A. F., Elterman, R. D., Munoz, L., Giller, C. A., & Winick, N. J. (2007). Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma. Journal of Neurosurgery, 107(1 Suppl), 5–10.PubMed
31.
Zurück zum Zitat Perreault, S., Lober, R. M., Carret, A. S., Zhang, G., Hershon, L., Décarie, J. C., Yeom, K., Vogel, H., Fisher, P. G., & Partap, S. (2013). Relapse patterns in pediatric embryonal central nervous system tumors. Journal of Neuro-Oncology, 115(2), 209–215.CrossRefPubMed Perreault, S., Lober, R. M., Carret, A. S., Zhang, G., Hershon, L., Décarie, J. C., Yeom, K., Vogel, H., Fisher, P. G., & Partap, S. (2013). Relapse patterns in pediatric embryonal central nervous system tumors. Journal of Neuro-Oncology, 115(2), 209–215.CrossRefPubMed
32.
Zurück zum Zitat Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., Agnihotri, S., Thompson, Y. Y., Kuzan-Fischer, C. M., Farooq, H., Isaev, K., Daniels, C., Cho, B. K., Kim, S. K., Wang, K. C., Lee, J. Y., Grajkowska, W. A., Perek-Polnik, M., Vasiljevic, A., Faure-Conter, C., Jouvet, A., Giannini, C., Nageswara Rao, A. A., Li, K. K. W., Ng, H. K., Eberhart, C. G., Pollack, I. F., Hamilton, R. L., Gillespie, G. Y., Olson, J. M., Leary, S., Weiss, W. A., Lach, B., Chambless, L. B., Thompson, R. C., Cooper, M. K., Vibhakar, R., Hauser, P., van Veelen, M., Kros, J. M., French, P. J., Ra, Y. S., Kumabe, T., López-Aguilar, E., Zitterbart, K., Sterba, J., Finocchiaro, G., Massimino, M., van Meir, E., Osuka, S., Shofuda, T., Klekner, A., Zollo, M., Leonard, J. R., Rubin, J. B., Jabado, N., Albrecht, S., Mora, J., van Meter, T., Jung, S., Moore, A. S., Hallahan, A. R., Chan, J. A., Tirapelli, D. P. C., Carlotti, C. G., Fouladi, M., Pimentel, J., Faria, C. C., Saad, A. G., Massimi, L., Liau, L. M., Wheeler, H., Nakamura, H., Elbabaa, S. K., Perezpeña-Diazconti, M., Chico Ponce de León, F., Robinson, S., Zapotocky, M., Lassaletta, A., Huang, A., Hawkins, C. E., Tabori, U., Bouffet, E., Bartels, U., Dirks, P. B., Rutka, J. T., Bader, G. D., Reimand, J., Goldenberg, A., Ramaswamy, V., & Taylor, M. D. (2017). Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell, 31(6), 737–754 e6.CrossRefPubMedPubMedCentral Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., Agnihotri, S., Thompson, Y. Y., Kuzan-Fischer, C. M., Farooq, H., Isaev, K., Daniels, C., Cho, B. K., Kim, S. K., Wang, K. C., Lee, J. Y., Grajkowska, W. A., Perek-Polnik, M., Vasiljevic, A., Faure-Conter, C., Jouvet, A., Giannini, C., Nageswara Rao, A. A., Li, K. K. W., Ng, H. K., Eberhart, C. G., Pollack, I. F., Hamilton, R. L., Gillespie, G. Y., Olson, J. M., Leary, S., Weiss, W. A., Lach, B., Chambless, L. B., Thompson, R. C., Cooper, M. K., Vibhakar, R., Hauser, P., van Veelen, M., Kros, J. M., French, P. J., Ra, Y. S., Kumabe, T., López-Aguilar, E., Zitterbart, K., Sterba, J., Finocchiaro, G., Massimino, M., van Meir, E., Osuka, S., Shofuda, T., Klekner, A., Zollo, M., Leonard, J. R., Rubin, J. B., Jabado, N., Albrecht, S., Mora, J., van Meter, T., Jung, S., Moore, A. S., Hallahan, A. R., Chan, J. A., Tirapelli, D. P. C., Carlotti, C. G., Fouladi, M., Pimentel, J., Faria, C. C., Saad, A. G., Massimi, L., Liau, L. M., Wheeler, H., Nakamura, H., Elbabaa, S. K., Perezpeña-Diazconti, M., Chico Ponce de León, F., Robinson, S., Zapotocky, M., Lassaletta, A., Huang, A., Hawkins, C. E., Tabori, U., Bouffet, E., Bartels, U., Dirks, P. B., Rutka, J. T., Bader, G. D., Reimand, J., Goldenberg, A., Ramaswamy, V., & Taylor, M. D. (2017). Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell, 31(6), 737–754 e6.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Ramaswamy, V., Remke, M., Bouffet, E., Faria, C. C., Perreault, S., Cho, Y. J., Shih, D. J., Luu, B., Dubuc, A. M., Northcott, P. A., Schüller, U., Gururangan, S., McLendon, R., Bigner, D., Fouladi, M., Ligon, K. L., Pomeroy, S. L., Dunn, S., Triscott, J., Jabado, N., Fontebasso, A., Jones, D. T., Kool, M., Karajannis, M. A., Gardner, S. L., Zagzag, D., Nunes, S., Pimentel, J., Mora, J., Lipp, E., Walter, A. W., Ryzhova, M., Zheludkova, O., Kumirova, E., Alshami, J., Croul, S. E., Rutka, J. T., Hawkins, C., Tabori, U., Codispoti, K. E., Packer, R. J., Pfister, S. M., Korshunov, A., & Taylor, M. D. (2013). Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. The Lancet Oncology, 14(12), 1200–1207.CrossRefPubMedPubMedCentral Ramaswamy, V., Remke, M., Bouffet, E., Faria, C. C., Perreault, S., Cho, Y. J., Shih, D. J., Luu, B., Dubuc, A. M., Northcott, P. A., Schüller, U., Gururangan, S., McLendon, R., Bigner, D., Fouladi, M., Ligon, K. L., Pomeroy, S. L., Dunn, S., Triscott, J., Jabado, N., Fontebasso, A., Jones, D. T., Kool, M., Karajannis, M. A., Gardner, S. L., Zagzag, D., Nunes, S., Pimentel, J., Mora, J., Lipp, E., Walter, A. W., Ryzhova, M., Zheludkova, O., Kumirova, E., Alshami, J., Croul, S. E., Rutka, J. T., Hawkins, C., Tabori, U., Codispoti, K. E., Packer, R. J., Pfister, S. M., Korshunov, A., & Taylor, M. D. (2013). Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. The Lancet Oncology, 14(12), 1200–1207.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Packer, R. J., Zhou, T., Holmes, E., Vezina, G., & Gajjar, A. (2013). Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961. Neuro-Oncology, 15(1), 97–103.CrossRefPubMed Packer, R. J., Zhou, T., Holmes, E., Vezina, G., & Gajjar, A. (2013). Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children’s Oncology Group trial A9961. Neuro-Oncology, 15(1), 97–103.CrossRefPubMed
35.
Zurück zum Zitat Kameda-Smith, M. M., Wang, A., Abdulhadi, N., Voth, R., Sergeant, A., Maharaj, A., Bakhshinyan, D., Adile, A. A., Pai, A. M., Ajani, O., Yarascavitch, B., Alyman, M. C., Duckworth, J., Samaan, M. C., Farrokhyar, F., Singh, S. K., Fleming, A., & Pediatric Brain Tumour Study Group. (2019). Salvage therapy for childhood medulloblastoma: a single center experience. The Canadian Journal of Neurological Sciences, 46(4), 403–414.CrossRefPubMed Kameda-Smith, M. M., Wang, A., Abdulhadi, N., Voth, R., Sergeant, A., Maharaj, A., Bakhshinyan, D., Adile, A. A., Pai, A. M., Ajani, O., Yarascavitch, B., Alyman, M. C., Duckworth, J., Samaan, M. C., Farrokhyar, F., Singh, S. K., Fleming, A., & Pediatric Brain Tumour Study Group. (2019). Salvage therapy for childhood medulloblastoma: a single center experience. The Canadian Journal of Neurological Sciences, 46(4), 403–414.CrossRefPubMed
36.
Zurück zum Zitat Robinson, G. W., et al. (2018). Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. The Lancet Oncology, 19(6), 768–784.CrossRefPubMedPubMedCentral Robinson, G. W., et al. (2018). Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. The Lancet Oncology, 19(6), 768–784.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Lafay-Cousin, L., Bouffet, E., Onar-Thomas, A., Billups, C. A., Hawkins, C., Eberhart, C., Horbinski, C., Robinson, G. W., Strother, D. R., Heier, L., Souweidane, M. M., Fouladi, M., Gajjar, A., & Children Oncology Group. (2017). ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age-a report of the Children Oncology Group. Journal of Clinical Oncology,35(15_suppl), 10505–10505.CrossRef Lafay-Cousin, L., Bouffet, E., Onar-Thomas, A., Billups, C. A., Hawkins, C., Eberhart, C., Horbinski, C., Robinson, G. W., Strother, D. R., Heier, L., Souweidane, M. M., Fouladi, M., Gajjar, A., & Children Oncology Group. (2017). ACNS1221: A phase II study for the treatment of non metastatic desmoplastic medulloblastoma in children less than 4 years of age-a report of the Children Oncology Group. Journal of Clinical Oncology,35(15_suppl), 10505–10505.CrossRef
39.
Zurück zum Zitat Perreault, S., Ramaswamy, V., Achrol, A. S., Chao, K., Liu, T. T., Shih, D., Remke, M., Schubert, S., Bouffet, E., Fisher, P. G., Partap, S., Vogel, H., Taylor, M. D., Cho, Y. J., & Yeom, K. W. (2014). MRI surrogates for molecular subgroups of medulloblastoma. AJNR. American Journal of Neuroradiology, 35(7), 1263–1269.CrossRefPubMedPubMedCentral Perreault, S., Ramaswamy, V., Achrol, A. S., Chao, K., Liu, T. T., Shih, D., Remke, M., Schubert, S., Bouffet, E., Fisher, P. G., Partap, S., Vogel, H., Taylor, M. D., Cho, Y. J., & Yeom, K. W. (2014). MRI surrogates for molecular subgroups of medulloblastoma. AJNR. American Journal of Neuroradiology, 35(7), 1263–1269.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Mata-Mbemba, D., Zapotocky, M., Laughlin, S., Taylor, M. D., Ramaswamy, V., & Raybaud, C. (2018). MRI characteristics of primary tumors and metastatic lesions in molecular subgroups of pediatric medulloblastoma: a single-center study. AJNR. American Journal of Neuroradiology, 39(5), 949–955.CrossRefPubMedPubMedCentral Mata-Mbemba, D., Zapotocky, M., Laughlin, S., Taylor, M. D., Ramaswamy, V., & Raybaud, C. (2018). MRI characteristics of primary tumors and metastatic lesions in molecular subgroups of pediatric medulloblastoma: a single-center study. AJNR. American Journal of Neuroradiology, 39(5), 949–955.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Lastowska, M., et al. (2018). Medulloblastoma with transitional features between group 3 and group 4 is associated with good prognosis. Journal of Neuro-Oncology, 138(2), 231–240.CrossRefPubMedPubMedCentral Lastowska, M., et al. (2018). Medulloblastoma with transitional features between group 3 and group 4 is associated with good prognosis. Journal of Neuro-Oncology, 138(2), 231–240.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Moxon-Emre, I., Bouffet, E., Taylor, M. D., Laperriere, N., Scantlebury, N., Law, N., Spiegler, B. J., Malkin, D., Janzen, L., & Mabbott, D. (2014). Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. Journal of Clinical Oncology, 32(17), 1760–1768.CrossRefPubMed Moxon-Emre, I., Bouffet, E., Taylor, M. D., Laperriere, N., Scantlebury, N., Law, N., Spiegler, B. J., Malkin, D., Janzen, L., & Mabbott, D. (2014). Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. Journal of Clinical Oncology, 32(17), 1760–1768.CrossRefPubMed
45.
Zurück zum Zitat ClinicalTrials.gov, A study assessing the feasibility of a surgery and chemotherapy-only in children with Wnt positive medulloblastoma. 2018, ethesda (MD): National Library of Medicine (US). ClinicalTrials.gov, A study assessing the feasibility of a surgery and chemotherapy-only in children with Wnt positive medulloblastoma. 2018, ethesda (MD): National Library of Medicine (US).
46.
Zurück zum Zitat ClinicalTrials.gov, Reduced craniospinal radiation therapy and chemotherapy in treating younger patients with newly diagnosed WNT-driven medulloblastoma. 2018, National Library of Medicine (US): Bethesda (MD). ClinicalTrials.gov, Reduced craniospinal radiation therapy and chemotherapy in treating younger patients with newly diagnosed WNT-driven medulloblastoma. 2018, National Library of Medicine (US): Bethesda (MD).
47.
Zurück zum Zitat ClinicalTrials.gov, A clinical and molecular risk-directed therapy for newly diagnosed medulloblastoma. 2013: Bethesda (MD): National Library of Medicine (US). ClinicalTrials.gov, A clinical and molecular risk-directed therapy for newly diagnosed medulloblastoma. 2013: Bethesda (MD): National Library of Medicine (US).
48.
Zurück zum Zitat ClinicalTrials.gov, International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma. 2014, ethesda (MD): National Library of Medicine (US). ClinicalTrials.gov, International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma. 2014, ethesda (MD): National Library of Medicine (US).
49.
Zurück zum Zitat Kameda-Smith, M. M., et al. (2013). Time to diagnosis of paediatric posterior fossa tumours: an 11-year west of Scotland experience 2000-2011. British Journal of Neurosurgery, 27(3), 364–369.CrossRefPubMed Kameda-Smith, M. M., et al. (2013). Time to diagnosis of paediatric posterior fossa tumours: an 11-year west of Scotland experience 2000-2011. British Journal of Neurosurgery, 27(3), 364–369.CrossRefPubMed
50.
Zurück zum Zitat Sergeant, A., et al. (2017). Analysis of surgical and MRI factors associated with cerebellar mutism. Journal of Neuro-Oncology, 133(3), 539–552.CrossRefPubMed Sergeant, A., et al. (2017). Analysis of surgical and MRI factors associated with cerebellar mutism. Journal of Neuro-Oncology, 133(3), 539–552.CrossRefPubMed
51.
Zurück zum Zitat Gottardo, N. G., Hansford, J. R., McGlade, J., Alvaro, F., Ashley, D. M., Bailey, S., Baker, D. L., Bourdeaut, F., Cho, Y. J., Clay, M., Clifford, S. C., Cohn, R. J., Cole, C. H., Dallas, P. B., Downie, P., Doz, F., Ellison, D. W., Endersby, R., Fisher, P. G., Hassall, T., Heath, J. A., Hii, H. L., Jones, D. T., Junckerstorff, R., Kellie, S., Kool, M., Kotecha, R. S., Lichter, P., Laughton, S. J., Lee, S., McCowage, G., Northcott, P. A., Olson, J. M., Packer, R. J., Pfister, S. M., Pietsch, T., Pizer, B., Pomeroy, S. L., Remke, M., Robinson, G. W., Rutkowski, S., Schoep, T., Shelat, A. A., Stewart, C. F., Sullivan, M., Taylor, M. D., Wainwright, B., Walwyn, T., Weiss, W. A., Williamson, D., & Gajjar, A. (2014). Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathologica, 127(2), 189–201.CrossRefPubMed Gottardo, N. G., Hansford, J. R., McGlade, J., Alvaro, F., Ashley, D. M., Bailey, S., Baker, D. L., Bourdeaut, F., Cho, Y. J., Clay, M., Clifford, S. C., Cohn, R. J., Cole, C. H., Dallas, P. B., Downie, P., Doz, F., Ellison, D. W., Endersby, R., Fisher, P. G., Hassall, T., Heath, J. A., Hii, H. L., Jones, D. T., Junckerstorff, R., Kellie, S., Kool, M., Kotecha, R. S., Lichter, P., Laughton, S. J., Lee, S., McCowage, G., Northcott, P. A., Olson, J. M., Packer, R. J., Pfister, S. M., Pietsch, T., Pizer, B., Pomeroy, S. L., Remke, M., Robinson, G. W., Rutkowski, S., Schoep, T., Shelat, A. A., Stewart, C. F., Sullivan, M., Taylor, M. D., Wainwright, B., Walwyn, T., Weiss, W. A., Williamson, D., & Gajjar, A. (2014). Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathologica, 127(2), 189–201.CrossRefPubMed
52.
Zurück zum Zitat ClinicalTrials.gov, A dose exploration study with MK-8628 in participants with selected advanced solid tumors (MK-8628-006). 2018, Bethesda (MD): National Library of Medicine (US). ClinicalTrials.gov, A dose exploration study with MK-8628 in participants with selected advanced solid tumors (MK-8628-006). 2018, Bethesda (MD): National Library of Medicine (US).
53.
Zurück zum Zitat ClinicalTrials.gov, A dose-finding study of MK-8628, a small molecule inhibitor of the bromodomain and extra-terminal (BET) proteins, in adults with selected advanced solid tumors (MK-8628-003). 2018, National Library of Medicine (US). Bethesda (MD). ClinicalTrials.gov, A dose-finding study of MK-8628, a small molecule inhibitor of the bromodomain and extra-terminal (BET) proteins, in adults with selected advanced solid tumors (MK-8628-003). 2018, National Library of Medicine (US). Bethesda (MD).
54.
Zurück zum Zitat Graff, J. N., Higano, C. S., Hahn, N. M., Taylor, M. H., Zhang, B., Zhou, X., Venkatakrishnan, K., Leonard, E. J., & Sarantopoulos, J. (2016). Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora a kinase inhibitor, with docetaxel in patients with solid tumors. Cancer, 122(16), 2524–2533.CrossRefPubMed Graff, J. N., Higano, C. S., Hahn, N. M., Taylor, M. H., Zhang, B., Zhou, X., Venkatakrishnan, K., Leonard, E. J., & Sarantopoulos, J. (2016). Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora a kinase inhibitor, with docetaxel in patients with solid tumors. Cancer, 122(16), 2524–2533.CrossRefPubMed
55.
Zurück zum Zitat Schoffski, P., et al. (2011). Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. European Journal of Cancer, 47(15), 2256–2264.CrossRefPubMed Schoffski, P., et al. (2011). Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. European Journal of Cancer, 47(15), 2256–2264.CrossRefPubMed
56.
Zurück zum Zitat Seymour, J. F., et al. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal, 4, e238.CrossRefPubMedPubMedCentral Seymour, J. F., et al. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal, 4, e238.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Bouffet, E. (2019). Management of high-risk medulloblastoma. Neurochirurgie. Bouffet, E. (2019). Management of high-risk medulloblastoma. Neurochirurgie.
58.
Zurück zum Zitat Thompson, E. M., et al. (2016). Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet Oncology. Thompson, E. M., et al. (2016). Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. The Lancet Oncology.
Metadaten
Titel
Pediatric medulloblastoma in the molecular era: what are the surgical implications?
verfasst von
Michelle M. Kameda-Smith
Publikationsdatum
24.02.2020
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1/2020
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-020-09865-y

Weitere Artikel der Ausgabe 1/2020

Cancer and Metastasis Reviews 1/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.